AN2 Therapeutics reports Q2 2026 results, updates timelines on three Phase 2 programs

AN2 Therapeutics reported financial results for the second quarter ended June 30, 2026, alongside updates across its three planned Phase 2 programs.

In polycythemia vera, the company held a pre-IND meeting with the FDA and now plans to expand the Phase 2 EBO-PV-201 study to add sites in the U.S. and Australia, with an IND filing expected in the third quarter of 2026.¹ As a result, Phase 2 enrollment is anticipated to begin in the fourth quarter of 2026, starting with an open-label sentinel cohort at a sub-therapeutic dose to assess pharmacokinetics and safety.¹ After the sentinel group concludes, a safety monitoring committee will guide dose selection for Part 1, a 28-week open-label evaluation of hematocrit control and phlebotomy frequency, with data expected periodically throughout 2027.¹

In M. abscessus lung disease, patient enrollment is ongoing in an 84-patient, multicenter, randomized, double-blind, placebo-controlled trial led by Dr. Kevin Winthrop of Oregon Health and Sciences University across an estimated 10-15 U.S. sites.¹ Topline results are anticipated in late 2027, subject to enrollment progress.¹

For chronic Chagas disease, a non-human primate study showed 100% parasitic elimination after 28 days of treatment with AN2-502998 at exposures attainable in humans, and a Phase 1 first-in-human study found the compound generally well tolerated at exposure levels consistent with those efficacy thresholds.¹ A Phase 2 proof-of-concept study in adults is planned to begin in late 2026.¹

On oncology, the company declared an ENPP1 development candidate for solid tumors and expects to advance a second development candidate by the end of 2026.¹

Financially, AN2 held $79.9 million in cash, cash equivalents and investments as of June 30, 2026, which it projects will fund operations into 2029 under its current plan.¹